Vališ Martin, Klímová Blanka, Novotný Michal, Herzig Roman
Department of Neurology, Faculty of Medicine and University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czechia.
Front Neurol. 2021 Feb 25;12:626106. doi: 10.3389/fneur.2021.626106. eCollection 2021.
The aim of this mini-review is to discuss the main antiplatelet agents that have been successfully used in the secondary prevention of non-cardioembolic ischemic stroke and transient ischemic attacks (TIA). The methodology is based on a literature review of available peer-reviewed English studies listed in PubMed. The findings reveal that aspirin remains a reliable antiplatelet agent in the secondary prevention of acute non-cardioembolic ischemic stroke and TIA. Nevertheless, currently, there are also other agents, i.e., ticagrelor, clopidogrel, and cilostazol, that can be applied. In addition, the results indicate that time is significant not only in severe stroke but also in non-severe stroke and TIA, which suggests that antiplatelet therapy should be applied within 24 h after the first symptoms because early treatment can lead to an improvement in neurological outcomes and reduce the chance of an early subsequent stroke.
本综述的目的是讨论已成功用于非心源性缺血性卒中及短暂性脑缺血发作(TIA)二级预防的主要抗血小板药物。方法基于对PubMed中列出的同行评审英文研究的文献综述。研究结果表明,阿司匹林在急性非心源性缺血性卒中和TIA的二级预防中仍然是一种可靠的抗血小板药物。然而,目前也有其他药物,即替格瑞洛、氯吡格雷和西洛他唑可以应用。此外,结果表明,时间不仅在严重卒中中很重要,在非严重卒中和TIA中也很重要,这表明抗血小板治疗应在首次症状出现后24小时内应用,因为早期治疗可改善神经功能结局并降低随后早期卒中的几率。